Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par
about
Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic OpportunitiesPhase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemiaBone marrow transplantation improves autoinflammation and inflammatory bone loss in SH3BP2 knock-in cherubism miceRandomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasTherapy of acute myeloid leukemia.Unrelated donor bone marrow transplantation in adults: some current controversies.Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARalpha rearrangement in newly diagnosed AML. The Medical Research Council (MRC) Adult Leukaemia Working Party.The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease.Management of relapsed acute myeloid leukaemia.Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Hematopoietic stem cell transplantation for leukemiaGene transfer and the treatment of haematological malignancy.High probability of long-term survival in 2-year survivors of autologous hematopoietic cell transplantation for AML in first or second CR.Unrelated donor hematopoietic transplantation.The role of bone marrow transplantation in acute promyelocytic leukemia.Therapeutic options for acute myelogenous leukemia.Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy?The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial.The search for optimal treatment in relapsed and refractory acute myeloid leukemia.Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis.Acute myeloid leukemia: treatment of adults under 60 years.Acute myeloid leukemia: treatment over 60.Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--an adult treater's view.Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicinThe treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature.Autologous stem cell transplantation for acute myeloid leukemia.WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies.T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysisStandardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study.Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMTAutologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia.The treatment of AML: current status and novel approaches.Treatment of AML in biological subgroups.Location, movement and survival: the role of chemokines in haematopoiesis and malignancy.Emerging Flt3 kinase inhibitors in the treatment of leukaemia.
P2860
Q26863756-BD19BDD9-0D8B-4823-87C3-2FF823A1816FQ27851579-8B3AE9D3-887A-4B3E-B3CC-56CAEDE82CC9Q28191301-E381956E-9A61-4400-9A65-888A4CC59732Q30009268-8D052A90-F273-4B45-B349-6CA52591621BQ30444746-12231E39-30CF-4F16-BCCF-F815500E07BBQ31893384-649475D3-7E2A-46C4-A538-0AA41C0C8233Q31929964-C80395D5-0B69-44A5-92CF-48E0A4A664F2Q33536887-8444F9F9-3C48-40CF-83E3-882DD95D8BB7Q33610823-04292282-F990-4D90-B71C-18CF67B5E2BDQ33723609-47B6E46E-426E-49A3-AE66-42361E633423Q33751243-F956FD5F-C458-44CC-BBBB-A3C896049FAAQ33978951-FC575E5D-43A7-49CF-B7B4-86E7E80F941CQ34034180-F586E0AF-B78E-4A10-AFD7-E28AB6A4F2B6Q34216677-FBE16AC2-FA6D-40F3-BCAC-925D9790E849Q34297698-AEC6F0B7-4C62-4ED1-8369-19768317BEECQ34326698-16EE6535-8090-4310-9D24-3848608C2EE1Q34355952-C0CC79E1-D5FC-4E31-9881-9205D26129C0Q34380840-C0BF0601-DDD4-428A-8E6C-6B74251BAD2DQ34452706-CAA1416B-C381-4CD8-8EE7-F7BDA45CAD7AQ34525604-9FB4B12D-FD29-4D14-8766-3BA651524E66Q34630777-AD972297-D084-45DA-92A2-FBCCDE515249Q34655572-50867C10-06DC-4E11-8AA4-88A4886360DBQ34679596-7FF94928-238A-4BEE-AEDD-57BA15C7DB58Q34680933-60DC6DA9-691C-42FD-B10D-4D74019A85DAQ34680938-BD177C10-E380-421F-9E9E-4BDF9565AB2FQ34760577-DDD2C3E1-AE6D-4B85-A734-FF97BE167CB8Q35029920-9C817D54-6429-426C-89E8-0B75F0256A34Q35103330-677DBE13-AC5B-41F3-95F2-DD0DED68CD81Q35122189-27AA400C-717A-4EDD-B666-E75003724593Q35166856-5B70E32C-416A-4DF3-80AE-512635F08A8EQ35236079-1777C4D6-6320-4F9E-9038-F695148512E3Q35561038-0568A026-AF16-4577-917C-9217B2BDADDEQ35643005-A19F22C4-28CF-4F2B-B66C-F5D128A097E2Q35847482-08565B8C-3B18-44F9-896A-AD4A7EF85F5DQ36121885-5AE9AE5D-55AA-4207-8C8B-DB9DC1D491DBQ36255287-3C69A4A4-31CB-4246-B604-073A380B5352Q36269943-2AD849D1-AB8A-498A-81C2-2F18393D08A2Q36308975-C14916B3-958E-4F39-8BF4-FF1662CE34E6Q36366975-B7E38A32-D977-487D-9392-AB47C2D4BE27Q36407425-B196ACF5-33B3-4593-9262-12E11AD3472B
P2860
Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par
description
1998 nî lūn-bûn
@nan
1998 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մարտին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Randomised comparison of addit ...... ildren's Leukaemia Working Par
@ast
Randomised comparison of addit ...... ildren's Leukaemia Working Par
@en
Randomised comparison of addit ...... ildren's Leukaemia Working Par
@nl
type
label
Randomised comparison of addit ...... ildren's Leukaemia Working Par
@ast
Randomised comparison of addit ...... ildren's Leukaemia Working Par
@en
Randomised comparison of addit ...... ildren's Leukaemia Working Par
@nl
prefLabel
Randomised comparison of addit ...... ildren's Leukaemia Working Par
@ast
Randomised comparison of addit ...... ildren's Leukaemia Working Par
@en
Randomised comparison of addit ...... ildren's Leukaemia Working Par
@nl
P2093
P1433
P1476
Randomised comparison of addit ...... en's Leukaemia Working Parties
@en
P2093
A H Goldstone
A K Burnett
K Wheatley
R M Stevens
P304
P356
10.1016/S0140-6736(97)09214-3
P407
P50
P577
1998-03-01T00:00:00Z